Medipal kept its growth machine running in the year to March 2026, with net sales reaching ¥3.82tn, ordinary income rising to ¥75.72bn and profit attributable to owners of the parent climbing to ¥42.53bn.
| Metric | Year to March 2025 | Year to March 2026 |
|---|---|---|
| Net sales | ¥3.67tn | ¥3.82tn |
| Ordinary income | ¥65.26bn | ¥75.72bn |
| Parent profit | ¥40.28bn | ¥42.53bn |
That is large in absolute terms and still notable as a trend rather than a one-off spike. Net sales were ¥3.67tn the previous year and ¥3.29tn four years earlier, while ordinary income was ¥65.26bn and parent profit ¥40.28bn a year earlier.
The filing summary also points readers to Good Distribution Practice and climate-related disclosure via Medipal’s TCFD materials, so the results are presented alongside compliance and sustainability references, not just yen totals. Investors looking for a fresh outlook will have to wait: this is the group’s annual securities report for the year ended March 31, 2026, not a new guidance release.